Company
Regenesis Biomedical
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
11
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$5.2M
1 Form D offering, 2011 to 2011
Equity
$5.2M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $5.2M raised, first sale Jun 2, 2011, 9 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jun 2, 2011 | Equity | $5.2M | Open-ended | 9 | Rule 506 | Form D ↗Jun 21, 2011 |
Company details
From the company's latest Form D.
- Legal name
- REGENESIS BIOMEDICAL INC
- Headquarters
- Scottsdale, Arizona
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- $5,000,001 - $25,000,000
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1172973 ↗
Executives, directors and promoters
As listed on the latest Form D.
8 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Regenesis Biomedical.
Latest FDA decisions
- Reprieve by RegenesisTM510(k)
K223620 · Decided May 24, 2023 · 170 days after receipt
Device type: Diathermy, Shortwave, For Use In Applying Therapeutic Deep Heat (IMJ) · Physical Medicine & Rehabilitation
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral NeuropathyPivotal-lookingCompleted
NCT03455543 · 182 participants · Start Mar 26, 2018 · Primary completion Nov 14, 2018
Device: Active Provant Therapy System; Inactive (sham) Provant Therapy System · For: Diabetic Neuropathy Peripheral
Sites: Mesa, Arizona; Northridge, California; Sacramento, California · 18 sites in all
10 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0887-2009 · Started Sep 29, 2008 · Posted by FDA Jan 26, 2009
Reason given: In the course of device testing, the firm determined that the affected devices may, under certain unusual clinical circumstance, be unable to generate a therapeutic dose of radio frequency energy. As such, for these few devices, the effectiveness of Provant therapy may be impaired.
Cause as FDA categorized it: Finished device change control · Device type: Diathermy, Shortwave, For Use Other Than Applying Therapeutic Deep Heat (ILX)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.